News service focusing on all aspects of the prevention, diagnosis, and management of a wide variety of infectious and sexually transmitted diseases, as well as antimicrobial resistance, and related molecular genetics, pathophysiology, and epidemiology.
Infectious diseases
Browse Archive: 
29 June 2015
The level of serum duplex-linear DNA increases markedly with liver disease progression and development of hepatocellular carcinoma in patients with chronic hepatitis B virus (HBV) infection, suggests research published in Gut.
29 June 2015
Hepatic alanine aminotransferase flares are associated with rapid decline and greater annual reductions of hepatitis B surface antigen in patients with chronic hepatitis B virus infection who achieve HBsAg seroclearance, say Japanese researchers.
17 June 2015
Fewer than three doses of the bivalent human papillomavirus vaccine may be sufficient to offer adequate protection against cervical HPV-16 and -18 infection, research published in The Lancet Oncology indicates.
01 June 2015
A meta-analysis of treatments for chronic hepatitis B virus infection suggests that tenofovir disoproxil fumarate is the most effective option for patients positive and negative for hepatitis B e antigen, but the latter group may also benefit from entecavir treatment.
01 June 2015
Tenofovir disoproxil fumarate monotherapy may be sufficient to maintain complete virological suppression in patients with chronic hepatitis B virus infection previously treated with TDF plus entecavir, suggests a review of patients.
01 June 2015
A Chinese team reports a correlation between serum levels of microRNA-181b and hepatitis B virus replication and disease progression in patients with chronic HBV infection.
28 April 2015
Tenofovir disoproxil fumarate alone elicits a response comparable to that of TDF plus entecavir in heavily pretreated patients with chronic hepatitis B virus infection resistant to adefovir dipivoxil, research suggests.
28 April 2015
In patients with chronic hepatitis B virus infection, treatment with tenofovir disoproxil fumarate does not significantly increase the risk of developing renal dysfunction compared with entecavir treatment, a US team reports.
Friendly links


Follow me on Twitter